Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Aerospan

Deal Watch November 2015

Strategic business expansion or financial engineering?In November Pfizer at long last found a willing acquisition target that may provide the tax inversion it has been desperate to achieve since its...

Deal Watch October 2015

A bumper crop of deals with seven transactions of $1bn or more

- PMLiVE

GSK’s severe asthma therapy Nucala gets EU nod

Becomes the first IL-5 inhibitor to be approved in the EU

- PMLiVE

Meda collaborates on asthma comic book

Launches new Explain Asthma volume at ACAAI annual meeting

- PMLiVE

GSK bags FDA approval for severe asthma drug Nucala

Drug to be launched as soon as possible

Pharma deals in September 2015

September saw an interesting mix of deal types and structures, disease areas and companies hitting our Deal Watch radar. Oncology deals continue to be prominent, but the month also saw...

- PMLiVE

CHMP backs GSK’s asthma antibody and Novartis’ heart failure drug

Positive opinions for GSK's IL-5 antibody and Novartis' potential $5bn-a-year brand

Pharma deals in August 2015

During a busy month AstraZeneca, Sanofi and Shire were among those hitting the headlines

Pharma deals in July 2015

A hot summer month for industry M&A, finds Medius Deal Watch

Pharma deals in June 2015

Allergan's $2.1bn acquisition of Kythera tops this month's deals

Teva Pharma logo

Teva set for FDA verdict on reslizumab early next year

Ruling for severe asthma therapy Cinquil expected by March 2016

- PMLiVE

GSK’s new asthma biologic gains FDA panel backing

British firm looking to help shore up its ageing respiratory portfolio 

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links